NKTR – Nektar Therapeutics
Nektar TherapeuticsNKTR
$0.6725Name : Nektar Therapeutics
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $125,154,944.00
EPSttm : -0.63
Nektar Therapeutics
$0.6725
0.34%$0.0023Float Short %
5.94
Margin Of Safety %
Put/Call OI Ratio
0.12
EPS Next Q Diff
0.04
EPS Last/This Y
-0.19
EPS This/Next Y
0.07
Price
0.67
Target Price
4.92
Analyst Recom
1.75
Performance Q
-21.64
Relative Volume
1.84
Beta
0.56
Ticker: NKTR
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-05-07 | NKTR | 0.6057 | 0.06 | 0.07 | 51248 |
| 2025-05-08 | NKTR | 0.6128 | 0.06 | 0.02 | 51529 |
| 2025-05-09 | NKTR | 0.5919 | 0.06 | 0.19 | 51847 |
| 2025-05-12 | NKTR | 0.7143 | 0.06 | 0.00 | 51729 |
| 2025-05-13 | NKTR | 0.7 | 0.06 | 0.00 | 54178 |
| 2025-05-14 | NKTR | 0.7124 | 0.06 | 0.04 | 55108 |
| 2025-05-15 | NKTR | 0.6729 | 0.06 | 0.04 | 55082 |
| 2025-05-16 | NKTR | 0.6805 | 0.06 | 0.00 | 55072 |
| 2025-05-19 | NKTR | 0.6907 | 0.05 | 0.01 | 44423 |
| 2025-05-20 | NKTR | 0.68 | 0.05 | 0.07 | 45123 |
| 2025-05-21 | NKTR | 0.6307 | 0.06 | 0.00 | 46328 |
| 2025-05-22 | NKTR | 0.6441 | 0.05 | 0.53 | 46822 |
| 2025-05-23 | NKTR | 0.6481 | 0.07 | 2.52 | 48189 |
| 2025-05-27 | NKTR | 0.6685 | 0.09 | 0.36 | 49095 |
| 2025-05-28 | NKTR | 0.6951 | 0.09 | 0.07 | 49257 |
| 2025-05-29 | NKTR | 0.7301 | 0.09 | 12.07 | 49470 |
| 2025-05-30 | NKTR | 0.7218 | 0.11 | 0.11 | 50077 |
| 2025-06-02 | NKTR | 0.7963 | 0.11 | 0.10 | 50478 |
| 2025-06-03 | NKTR | 0.7499 | 0.11 | 0.07 | 51762 |
| 2025-06-04 | NKTR | 0.7398 | 0.11 | 0.38 | 52102 |
| 2025-06-05 | NKTR | 0.6744 | 0.12 | 0.08 | 52251 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-05-07 | NKTR | 0.61 | 1.3 | - | -0.72 |
| 2025-05-08 | NKTR | 0.62 | 1.3 | - | -0.72 |
| 2025-05-09 | NKTR | 0.59 | 1.3 | - | -0.72 |
| 2025-05-12 | NKTR | 0.71 | 1.3 | - | -0.72 |
| 2025-05-13 | NKTR | 0.71 | -2.3 | - | -0.72 |
| 2025-05-14 | NKTR | 0.71 | -2.3 | - | -0.72 |
| 2025-05-15 | NKTR | 0.68 | -2.3 | - | -0.72 |
| 2025-05-16 | NKTR | 0.68 | -2.3 | - | -0.73 |
| 2025-05-19 | NKTR | 0.69 | -6.9 | - | -0.73 |
| 2025-05-20 | NKTR | 0.69 | -6.9 | - | -0.73 |
| 2025-05-21 | NKTR | 0.63 | -6.9 | - | -0.73 |
| 2025-05-22 | NKTR | 0.64 | -6.9 | - | -0.73 |
| 2025-05-23 | NKTR | 0.65 | -6.9 | - | -0.73 |
| 2025-05-27 | NKTR | 0.67 | 1.1 | - | -0.77 |
| 2025-05-28 | NKTR | 0.70 | 1.1 | - | -0.77 |
| 2025-05-29 | NKTR | 0.73 | 1.1 | - | -0.77 |
| 2025-05-30 | NKTR | 0.72 | 1.1 | - | -0.77 |
| 2025-06-02 | NKTR | 0.79 | 1.1 | - | -0.77 |
| 2025-06-03 | NKTR | 0.75 | 1.1 | - | -0.77 |
| 2025-06-04 | NKTR | 0.75 | 1.1 | - | -0.77 |
| 2025-06-05 | NKTR | 0.67 | 1.1 | - | -0.77 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-05-07 | NKTR | -4.38 | -8.02 | 4.54 |
| 2025-05-08 | NKTR | -4.38 | -8.02 | 4.54 |
| 2025-05-09 | NKTR | -4.38 | -8.02 | 4.54 |
| 2025-05-12 | NKTR | -4.38 | -6.55 | 4.98 |
| 2025-05-13 | NKTR | -4.38 | -6.55 | 4.98 |
| 2025-05-14 | NKTR | -4.38 | -6.55 | 4.98 |
| 2025-05-15 | NKTR | -4.38 | -6.55 | 4.98 |
| 2025-05-16 | NKTR | -4.38 | -6.55 | 4.98 |
| 2025-05-19 | NKTR | -4.38 | -10.78 | 4.98 |
| 2025-05-20 | NKTR | -4.38 | -10.78 | 4.98 |
| 2025-05-21 | NKTR | -3.97 | -10.78 | 4.98 |
| 2025-05-22 | NKTR | -4.56 | -10.78 | 4.98 |
| 2025-05-23 | NKTR | -4.56 | -10.78 | 4.98 |
| 2025-05-27 | NKTR | -4.56 | -7.07 | 4.98 |
| 2025-05-28 | NKTR | -4.60 | -7.07 | 5.94 |
| 2025-05-29 | NKTR | -4.60 | -7.07 | 5.94 |
| 2025-05-30 | NKTR | -4.60 | -7.07 | 5.94 |
| 2025-06-02 | NKTR | -4.60 | -6.75 | 5.94 |
| 2025-06-03 | NKTR | -4.60 | -6.75 | 5.94 |
| 2025-06-04 | NKTR | -4.60 | -6.75 | 5.94 |
| 2025-06-05 | NKTR | -4.60 | -6.75 | 5.94 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.22
Avg. EPS Est. Current Quarter
-0.18
Avg. EPS Est. Next Quarter
-0.18
Insider Transactions
-4.6
Institutional Transactions
-6.75
Beta
0.56
Average Sales Estimate Current Quarter
10
Average Sales Estimate Next Quarter
10
Fair Value
Quality Score
31
Growth Score
29
Sentiment Score
39
Actual DrawDown %
97.5
Max Drawdown 5-Year %
-98.3
Target Price
4.92
P/E
Forward P/E
PEG
P/S
1.44
P/B
9.14
P/Free Cash Flow
EPS
-0.64
Average EPS Est. Cur. Y
-0.77
EPS Next Y. (Est.)
-0.7
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-152.49
Relative Volume
1.84
Return on Equity vs Sector %
-992.4
Return on Equity vs Industry %
-974.6
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.05
EBIT Estimation
Nektar TherapeuticsSector: Healthcare
Industry: Biotechnology
Employees: 61
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
stock quote shares NKTR – Nektar Therapeutics Stock Price stock today
news today NKTR – Nektar Therapeutics stock forecast ,stock prediction 2023 2024 2025
marketwatch NKTR – Nektar Therapeutics yahoo finance google finance
stock history NKTR – Nektar Therapeutics invest stock market
stock prices NKTR premarket after hours
ticker NKTR fair value insiders trading